Fifty methicillin and multi-resistant Staphylococcus haemolyticus (MRSH) strains, were tested against daptomycin and comparators. Daptomycin showed an overall MIC90 value of 1 mg/L, similar to that of quinopristin/dalfopristin and lower than the values for vancomycin (2 mg/L), linezolid (2 mg/L) and teicoplanin (32 mg/L). Eighteen strains showed heteroresistant subpopulations with teicoplanin, whereas two strains were also heteroresistant to vancomycin and these sub-populations retained susceptibility to daptomycin. Our results show the good in vitro activity of daptomycin in MRSH strains possessing a multi-resistant phenotype. Clinical data on daptomycin efficacy are necessary to confirm our in vitro findings. © 2008 Elsevier Inc. All rights reserved.
In vitro activity of daptomycin against methicillin- and multi-resistant Staphylococcus haemolyticus invasive isolates carrying different mec complexes / Campanile, Floriana; Bongiorno, Dafne; Borbone, Sonia; Falcone, Marco; Giannella, Maddalena; Venditti, Mario; Stefani, Stefania. - In: DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE. - ISSN 0732-8893. - ELETTRONICO. - 61:2(2008), pp. 227-231. [10.1016/j.diagmicrobio.2008.01.019]
In vitro activity of daptomycin against methicillin- and multi-resistant Staphylococcus haemolyticus invasive isolates carrying different mec complexes
GIANNELLA, MADDALENA;
2008
Abstract
Fifty methicillin and multi-resistant Staphylococcus haemolyticus (MRSH) strains, were tested against daptomycin and comparators. Daptomycin showed an overall MIC90 value of 1 mg/L, similar to that of quinopristin/dalfopristin and lower than the values for vancomycin (2 mg/L), linezolid (2 mg/L) and teicoplanin (32 mg/L). Eighteen strains showed heteroresistant subpopulations with teicoplanin, whereas two strains were also heteroresistant to vancomycin and these sub-populations retained susceptibility to daptomycin. Our results show the good in vitro activity of daptomycin in MRSH strains possessing a multi-resistant phenotype. Clinical data on daptomycin efficacy are necessary to confirm our in vitro findings. © 2008 Elsevier Inc. All rights reserved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
